Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 30, 2026

Revenue from Contract with Customer [Abstract]

The following table summarizes revenue by source as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2026		2025		2026		2025
Major Products /Service Lines
Product revenue, net(1)	$	378,367	$	376,687	$	1,125,149	$	1,118,152
License and royalty revenues		11,546		7,327		30,277		16,671
Total revenues	$	389,913	$	384,014	$	1,155,426	$	1,134,823

(1)

The Company’s product revenue includes PYLARIFY, Neuraceq, DEFINITY, and prior to January 1, 2026, TechneLite, among other products. TechneLite was sold in connection with the Company’s sale of its single-photon emission computerized tomography (“SPECT”) business to SHINE Technologies, LLC (“SHINE”), a wholly-owned subsidiary of Illuminated Holdings, Inc. (“Illuminated”), on January 1, 2026. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all its principal products.

Revenue by product category on a net basis is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2026		2025		2026		2025
PYLARIFY	$	238,930	$	240,616	$	720,220	$	748,912
Total oncology		238,930		240,616		720,220		748,912
Neuraceq		45,577		20,442		120,632		20,442
Total neurology		45,577		20,442		120,632		20,442
DEFINITY		85,673		81,785		258,579		244,935
Total cardiology		85,673		81,785		258,579		244,935
Strategic partnerships and other		19,733		13,705		55,995		36,042
SPECT		—		27,466		—		84,492
Total revenues	$	389,913	$	384,014	$	1,155,426	$	1,134,823

Schedule of Revenue by Geographic Region Determined by Location of Customer or Other Party

The following table presents the Company’s revenue by geographic region determined by location of customer or other party for the periods presented:


	Three Months Ended September 30,										Nine Months Ended September 30,
(in thousands)	2026		% of Revenue			2025		% of Revenue			2026		% of Revenue			2025		% of Revenue
United States	$	379,019		97.2	%	$	364,069		94.8	%	$	1,101,736		95.4	%	$	1,078,128		95.0	%
Rest of world		10,894		2.8	%		19,945		5.2	%		53,690		4.6	%		56,695		5.0	%
Total revenues	$	389,913		100.0	%	$	384,014		100.0	%	$	1,155,426		100.0	%	$	1,134,823		100.0	%

Schedule of Amount of and Change in Accruals for Rebate Liabilities

An analysis of the amount of, and change in, accruals for rebate liabilities is summarized as follows:


(in thousands)	Rebates
Balance at January 1, 2026	$	66,448
Provision related to current period revenues		162,046
Payments or credits made during the period		(156,254	)
Balance at September 30, 2026	$	72,240

Schedule of Deferred Revenue

The following table provides a roll forward of deferred revenue:


(in thousands)	Deferred Revenue
Balance at January 1, 2026	$	6,984
Revenue recognized in relation to the beginning of the year contract liability balance		(4,408	)
Revenue deferred		6,792
Balance at September 30, 2026	$	9,368